Atai Life Sciences N.V. (ATAI)

Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?

Atai Life Sciences N.V. (ATAI) reached a significant support level, and could be a good pick for investors from a technical perspective.

Here is how atai Life Sciences N.V. (ATAI) and Cardinal Health (CAH) have performed compared to their sector so far this year.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later in 2025, according to Jefferies analysts, following another batch of positi...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline data from Part 2 of Beckley Psytech's Phase 2a study of BPL-003, an intranasal formulation of mebufotenin benzoate, in combinat...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' stock is poised to climb significantly, driven by a series of clinical catalysts this year and next, analysts at Jefferies wrote following the release of the...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has kicked off 2025 with strong momentum across its clinical pipeline ahead of expected key data readouts later this year and into 2026. Recent operational hi...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has dosed the first patient in its Phase 2 clinical trial of EMP-01 for the treatment of social anxiety disorder (SAD). EMP-01, an oral form...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical reado...

After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have h...